Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A

NCT02941354 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Congenital Bleeding Disorder
Haemophilia A

Interventions

DRUG: turoctocog alfa

Sponsor

Novo Nordisk A/S